Latest NS5 Stories
NEW YORK, Oct.
FREDERICK, Md., May 14 /PRNewswire/ -- ImQuest Bio and Arisyn jointly presented important new results on ATI-0810 (Formerly PG301029), a novel late stage inhibitor of hepatitis C virus (HCV) replication, at the 13th ISVHLD meeting held last week in Washington D.C.
BRISBANE, Calif., March 18 /PRNewswire-FirstCall/ -- InterMune, Inc.
PALO ALTO, Calif., Feb. 24 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., a start-up biotechnology company developing antiviral therapies, announced that it has raised $7.1 million in a Series A financing co-led by InterWest Partners and Vivo Ventures.
SAN FRANCISCO, Nov.
Genelabs Technologies, Inc. (Nasdaq:GNLB) announced that three presentations were made at the 15th International Symposium on Hepatitis C Virus and Related Viruses, each on a non-nucleoside hepatitis C virus (HCV) polymerase inhibitor discovered by Genelabs.
BRISBANE, Calif., Sept. 24 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that four abstracts from clinical and in-vitro studies of ITMN-191 (R7227) accepted for presentation at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, Oct. 31 - Nov.
- The act of sweetening by admixture of some saccharine substance.